Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus

Shohreh Shahabi, Ilenia Pellicciotta, June Hou, Sarah Graceffa, Gloria S. Huang, Robert N. Samuelson, Gary L. Goldberg

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix. Consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics.

Original languageEnglish (US)
Pages (from-to)129-131
Number of pages3
JournalRare Tumors
Volume3
Issue number4
DOIs
StatePublished - 2011

Keywords

  • Chromogranin A
  • Large cell neuroendocrine carcinoma
  • Octerotide
  • Uterine corpus

ASJC Scopus subject areas

  • Histology
  • Oncology

Fingerprint Dive into the research topics of 'Clinical utility of chromogranin A and octreotide in large cell neuro endocrine carcinoma of the uterine corpus'. Together they form a unique fingerprint.

Cite this